Diligence memo · auto-generated · as of July 3, 2026
Medicenna Therapeutics Inc.
Medicenna Therapeutics Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Medicenna Therapeutics Inc. operates in Pharmaceuticals, based in VANCOUVER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Medicenna Therapeutics Inc. has raised $742K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $798K on 2016-04-05.
Most recent recorded round closed around 2016-04-05.
Valuation (modeled)modeled
Provath models Medicenna Therapeutics Inc. at approximately $28M (range $561K–$221M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.47× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 10.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 15% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: Chase Therapeutics Corp, Acura Pharmaceuticals, Inc, Paragon Biosciences Skyline Capital, LLC, Phoenix PharmaLabs Inc, Saghmos Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.